EGFRvIII-DBTE

EGFRvIII-DBTE is an experimental DNA-encoded bispecific T cell engager (DBTE) designed for the treatment of glioblastoma multiforme (GBM). Developed by researchers at The Wistar Institute and the University of Pennsylvania, the therapy utilizes a DNA plasmid platform to deliver the genetic sequence for a bispecific antibody fragment. Once administered via intramuscular injection, the host's cells express and secrete the bispecific protein, which simultaneously targets the tumor-specific mutation EGFR variant III (EGFRvIII) and the CD3 complex on T cells. This dual binding facilitates the recruitment and activation of T cells directly at the tumor site, leading to targeted cytotoxicity against EGFRvIII-expressing glioma cells. In preclinical orthotopic GBM models, EGFRvIII-DBTE has demonstrated the ability to induce tumor clearance and provide durable in vivo expression of the therapeutic engager, potentially overcoming the pharmacokinetic limitations of traditional recombinant bispecific T cell engagers.